Home
Company
About us
Management
Board of Directors
Scientific Advisory Board
Partnerships
Partnerships
Nox Science
NOX Enzymes
NADPH Oxidase
NOX Enzyme Family
NOX Expression
NOX and Disease
Oxidative Stress and Disease
Physiological Functions of NOX
Fibrotic diseases
Neurodegenerative diseases
Cardiovascular diseases
Publications
Pipeline
GKT831
GKT771
Research programs
Investors
Stock information
Analyst coverage
Contribution project
Press release
Project presentation
Documentation
Shareholders general meeting
Press releases
2018
2017
2016
2015
2014
Events and presentations
Regulated information
Financial information
2018
2017
2016
2015
2014
Other regulated information
2018
2017
2016
2015
2014
Governance
OCABSA warrants
Shareholder information
Shareholders’ meetings
2018
2017
AGM of June 15, 2017
AGM of February 28, 2017
2016
2015
2014
Agenda
News and Events
Press releases
2018
2017
2016
2015
2014
Events and presentations
Media
Press clippings
Interviews
Contacts
News
See all news
Prev
Next
2018-11-05 - 07:00
Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints ...
2018-10-29 - 07:00
Genkyotex Announces Positive Outcome from the Independent SMB’s Thir...
2018-10-24 - 18:00
Genkyotex provides corporate update and reports cash position at Septe...
2018-10-15 - 07:00
Genkyotex Announces Presentation of GKT831 Efficacy Data in a Preclini...
2018-10-08 - 07:00
Preclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presen...
2018-09-26 - 17:45
Genkyotex Announces First-Half 2018 Financial Results
2018-09-26 - 07:00
Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with ...
2018-09-03 - 17:45
Genkyotex Announces Positive Outcome from the Second Independent SMB R...
Events
See all events
2018-11-05 - 15:00
Management presentation on positive interim Phase 2 results in PBC
2018-11-13 - 09:00
Investor Presentation November 2018
